NDAORALTABLET
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
6/8 — Strong
JESDUVROQ (daprodustat) by GSK is hypoxia-inducible factor prolyl hydroxylase inhibitors [moa]. Approved for hypoxia-inducible factor prolyl hydroxylase inhibitor [epc]. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JESDUVROQ (daprodustat) is an oral small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor approved in February 2023 for treating anemia. It works by stabilizing HIF-α proteins to boost endogenous erythropoietin production, offering a new oral alternative to traditional ESA therapies in nephrology and oncology settings.
Peak11.5 years to LOE
Product is at peak commercial stage post-approval; GSK is scaling brand and field teams to capture market share in the anemia treatment landscape.
Mechanism of Action
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
Pharmacologic Class:
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Started Dec 2025
100 enrolled
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Started Sep 2023
4 enrolled
Anaemia
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
Started Jul 2023
161 enrolled
AnemiaRenal Insufficiency, ChronicRenal Anemia
Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants
Started Dec 2020
259 enrolled
Anaemia
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Started Jul 2019
15 enrolled
Anaemia
Worked on JESDUVROQ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.